Filing Flows › Bioventus (BVS) › Q2 2026
Bioventus (BVS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Bioventus (BVS) reported revenue of $153M for the second quarter 2026 (Q2 2026), +4% from a year earlier and +16% from the quarter before. Operating margin was 12.5%, net earnings $33.4M (21.8% of revenue).
Bioventus, Q2 2026: revenue $153M (+4% year over year), operating margin 12.5%, net earnings $33.4M, operating cash flow $19.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $153M | +16% | +4% |
| Gross profit | $106M | +16% | +4% |
| Operating profit | $19.1M | +127% | +4% |
| Net earnings | $33.4M | +974% | +348% |
| Operating cash flow | $19.9M | +122% | -23% |
| Free cash flow | $18.9M | +126% | -25% |
What changed
Revenue was $153.2M in Q2 2026, up 4% year over year and up 16% from the previous quarter.
Gross margin was 69.0%, down 0.2 points from Q2 2025. Operating profit was $19.1M, a 12.5% margin (unchanged year over year). Of the extra revenue versus Q2 2025, 14% reached operating profit, above the 12% margin then. Operating expenses grew 3% against revenue growth of 4%. Net earnings were $33.4M, up 348% year over year. The tax line was a benefit of $20.9M on pre-tax earnings of $15.3M.
Operating cash flow was $19.9M (down 23% year over year), 55% of net income including minority interests. Non-cash charges added back $10.9M of depreciation and amortization and $5.0M of share-based compensation. Working capital and other items used $32.3M. Capital expenditures of $1.0M left free cash flow of $18.9M.
Questions
What was Bioventus' revenue in the second quarter 2026?
Bioventus (BVS) reported revenue of $153M for the second quarter 2026 (Q2 2026), +4% from a year earlier and +16% from the quarter before.
Was Bioventus profitable in the second quarter 2026?
Operating profit was $19.1M (12.5% of revenue) and net earnings $33.4M.
Source: Bioventus 10-Q on SEC EDGAR.